Stock market today: S&P 500 falls as government shutdown, trade jitters persist
Investing.com - Barclays has reiterated its Equalweight rating on Alcon Inc. (NYSE:ALC) stock, maintaining its price target of $86.00. The target represents significant upside from the current price of $72.05, with the stock trading near its 52-week low of $71.55. According to InvestingPro data, the company maintains a GOOD financial health score.
The research firm’s assessment comes as part of its ongoing coverage of the eye care company, which specializes in surgical equipment and vision care products.
Alcon, which was spun off from Novartis in 2019, continues to operate in the global ophthalmology market with its portfolio of contact lenses, eye drops, surgical equipment, and intraocular lenses.
The maintained Equalweight rating suggests Barclays views Alcon’s stock as likely to perform in line with the sector average over the next 12 months.
The unchanged $86.00 price target indicates Barclays’ analysis of Alcon’s future earnings potential, market position, and growth prospects remains consistent with its previous evaluation.
In other recent news, STAAR Surgical Company is at the center of a contentious acquisition proposal by Alcon Inc. The company’s board is advocating for the $28.00 per share all-cash offer from Alcon, which is a 59% premium over STAAR’s 90-day volume-weighted average price before the announcement. However, significant opposition has emerged from major shareholders and advisory firms. Broadwood Partners, holding a 27.5% stake in STAAR, has urged shareholders to reject the offer, citing concerns about the board’s decision-making and the management’s reduced financial projections. Similarly, Yunqi Capital, with a 5.1% stake, opposes the deal, arguing that it undervalues STAAR’s potential, especially in the Chinese market. Glass Lewis, a leading proxy advisory firm, also recommended voting against the acquisition, raising issues about the sale process and valuation. These developments indicate a divided opinion among stakeholders regarding the future direction of STAAR Surgical Company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.